Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2476 to 2490 of 7683 results

  1. Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A [ID6170]

    In development [GID-TA11106] Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Anhydrous sodium thiosulfate (Pedmarqsi) for preventing ototoxicity caused by cisplatin chemotherapy in people aged 1 month to 17 years with localised solid tumours [ID1001]

    In development [GID-TA10611] Expected publication date: 18 December 2024

    Technology appraisal guidance
    In development

  3. PillCam COLON 2 for investigation of the colon through direct visualisation

    In development [GID-DG10083] Expected publication date: 17 July 2025

    Diagnostics guidance
    In development

  4. Olipudase alfa for treating Niemann-Pick disease types A and B [ID3913 ]

    In development [GID-HST10060] Expected publication date: TBC

    Highly specialised technologies guidance
    In development

  5. Fosdenopterin for treating molybdenum cofactor deficiency type A [ID6264]

    In development [GID-HST10055] Expected publication date: 29 January 2025

    Highly specialised technologies guidance
    In development

  6. Pneumonia QS update: topic engagement

    We are listening to your views on this Quality standard. Comments close 21 November 2024.

    Quality standard
    In consultation

  7. Advanced breast cancer: diagnosis and management (Partial update)

    In development [GID-NG10430] Expected publication date: TBC

    NICE guideline
    In development

  8. Pneumonia QS update

    In development [GID-QS10190] Expected publication date: 14 August 2025

    Quality standard
    In development

  9. Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 2 therapies [ID5108]

    Awaiting development [GID-TA11018] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Advanced breast cancer: diagnosis and management (Partial update): draft scope consultation

    We are listening to your views on this NICE guideline. Comments close 21 November 2024.

    NICE guideline
    In consultation

  11. Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6328]

    In development [GID-TA11408] Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection (Review of TA761) [ID5120]

    In development [GID-TA11369] Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (MA review of TA760) [ID6293]

    In development [GID-TA11480] Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack (DG59)

    Evidence-based recommendations on CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack

    Diagnostics guidance
    Published
    31 July 2024
    View recommendations

    Sections for DG59

  15. Adalimumab for treating early Dupuytren's contracture [ID6276]

    Awaiting development [GID-TA11363] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development